Skip to main content
. 2012 Sep 13;14(4):915–924. doi: 10.1208/s12248-012-9406-x

Table III.

Number of Failed BE Studies Reviewed at FDA’s OGD Since the “All Bioequivalence Studies” Rule Became Effective in July 2009

Description BE Studies ANDAs
Number Percent of total Number Percent of total
Within-subject variability of AUC and C max ≥ 30% 92 45 45 37
Within-subject variability of AUC and C max < 30% 113 55 76 63
Totals 205 100 121 100